InvestorsHub Logo
Followers 15
Posts 1647
Boards Moderated 0
Alias Born 05/15/2015

Re: None

Monday, 04/03/2017 7:34:06 PM

Monday, April 03, 2017 7:34:06 PM

Post# of 19457
GOVX: Zika platform at CENTER of NIH $100M trials.


NOTE: The NIH news today concerning the HIV vax effort put GOVX in the top tier of HIV related bio/pharmas

The NIH is also placing a priority on the GOVX based platform for the Zika vax trials that is now kicking into high gear.

My standing advice is to buy 500,000 shares of GOVX and sit back.

If it drops, buy more.


Here is the NIH Zika news:
http://hosted.ap.org/dynamic/stories/U/US_MED_ZIKA_VACCINE?SITE=AP&SECTION=HOME&TEMPLATE=DEFAULT&CTIME=2017-03-31-14-55-50


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GOVX News